Education > Continuing Education

Web-Based Lectures

Previously recorded webinars are available through the LearnSTAT OnDemand program.

Current Webinar Offerings:


November 4, 2014 Coordinating Collection, Analysis and Submission of Clinical Trials Data with Metadata Standards - Focus on Analysis Deliverables (Part 2 of 2)
November 18, 2014 Bayesian Combination Dose Finding: Concepts and Applications
December 4, 2014 From Sample Size Calculations to Clinical Trial Optimization




Back to top

Title: Coordinating Collection, Analysis and Submission of Clinical Trials Data with Metadata Standards - Focus on Analysis Deliverables (Part 2 of 2)
Presenter: Steve Kirby, Mario Widel and Luke Reinbolt
Date and Time: Tuesday, November 4, 2014, 12 p.m. - 1:30 p.m. Eastern time
Sponsor: Section for Statistical Programmers and Analysts

Registration Deadline: Friday, October 31, at 12:00 p.m. Eastern time

Description:
Starting with a diagram that links key submission deliverables and associated metadata, the authors will share how companies can plan to have key content needed to support study planning and generation of CDISC data, TFLs and associated documentation available as metadata and will discuss how that metadata can support operational efficiency and a transparent, traceable path from study planning to regulatory submission.

For each deliverable, the authors will explore the use case for a metadata driven approach, share a specific, concrete process example and investigate how the content is related to other aspects of the clinical trials process.

Part 2 will focus on analysis deliverables and associated metadata. As what actually happens in a study (or related studies) impacts analysis, this analysis content is in some cases impacted by tabulations content presented in Part 1. Key content areas will be: ADaM metadata and ADaM mapping code; TFL metadata and TFL code; and associated submission documentation (define.xml, Reviewer's Guide).

Registration Fees:
Member of the Section for Statistical Programmers and Analysts: $40
ASA Member: $65
Nonmember: $85

Each registration is allowed one web connection and one audio connection. Multiple persons are encouraged to view each registered connection (for example, by projecting the webinar in a conference room).

Registration is Closed

Access Information
Registered persons will be sent an email the afternoon of Friday, October 31, with the access information to join the webinar and the link to download and print a copy of the presentation slides.




Back to top

Title: Bayesian Combination Dose Finding: Concepts and Applications
Presenter: Simon Wandel (Novartis Pharma AG) and Suman Sen (Novartis Pharmaceutical Company)
Date and Time: Tuesday, November 18, 2014, 12:00 p.m. - 2:00 p.m. Eastern time
Sponsor: Biopharmaceutical Section

Registration Deadline: Friday, November 14, at 12:00 p.m. Eastern time

Description:
Particular interest in Bayesian model-based dose finding has been observed in recent years. Multiple publications of successful single-agent phase I Oncology studies undermine the related paradigm shift which happened at some Pharmaceutical companies already and is ongoing in others. However, nowadays single agent dose finding is not the only goal in early development; rather, combination dose finding starts to play an important role which poses new challenges to clinical teams and statisticians.

In this webinar, an introduction to the statistical concept of Bayesian model-based dose finding with a particular emphasis on the combination setting will be provided. Based on practical experience, a special section will be devoted to the selection of the starting dose combination where both, statistical modeling and clinical considerations play an important role. Real case studies will be used to illustrate concepts and methods along with potential pitfalls which should be avoided. Finally, based on a literature search and on personnel communication, an overview of the current trends and adaption in the United States and in Europe will be provided.

Registration Fees:
Biopharmaceutical Section Members: $44
ASA Members: $59
Nonmembers: $74

Each registration is allowed one web connection and one audio connection. Multiple persons are encouraged to view each registered connection (for example, by projecting the webinar in a conference room).

Register



Access Information
Registered persons will be sent an email the afternoon of Friday, November 14, with the access information to join the webinar and the link to download and print a copy of the presentation slides.




Back to top

Title: From Sample Size Calculations to Clinical Trial Optimization
Presenters: Alex Dmitrienko, Quintiles, and  Gautier Paux, Servier
Date and Time: Thursday, December 4, 2014, 12:00 p.m. – 2:00 p.m. Eastern time
Sponsor: Biopharmaceutical Section

Registration Deadline: Tuesday, December 2, at 12:00 p.m. Eastern time

Description:
It is well known that sample size determination is one of the key aspects of designing a new clinical trial.  A standard sample size calculation approach generally pursues a simple goal of computing a quick estimate of the required number of patients or events.  Closed-form solutions are normally preferred, which often forces the trial’s sponsor to make simplifying assumptions. The clinical scenario evaluation (CSE) framework introduced in Benda et al (2010) provides an extended version of this basic “one-dimensional” approach.  Clinical scenario evaluation focuses on a broad “multi-dimensional” approach to a quantitative assessment of the operating characteristics of several candidate analysis methods under multiple candidate trial designs to arrive at a solution which is consistent with the trial’s clinical objectives and maximizes a relevant success criterion or utility function.
 
In this webinar we will introduce the key principles of clinical scenario evaluation in the context of Phase II and Phase III clinical trials and touch upon multiple related approaches.  We will discuss the general concept of clinical trial optimization aimed at identifying the configurations of applicable design scenarios and analysis strategies that lead to optimal performance.  We will also emphasize the importance of sensitivity assessments to ensure that an optimal clinical trial design is robust to reasonable deviations from the assumed parameter values.
 
The CSE approach will be illustrated using case studies based on a clinical trial with multiple objectives, clinical trial with a biomarker-driven design and an adaptive Phase II clinical trial.  Finally, we will introduce an R package (Mediana package) which was developed to provide a general software implementation of the CSE approach. The current version of the Mediana package supports a broad set of clinical trial designs and analysis methods, and we will discuss new features that will be added in the future.
 
References
Benda, N., Branson, M., Maurer, W., Friede, T. (2010). Aspects of modernizing drug development using clinical scenario planning and evaluation. Drug Information Journal. 44, 299-315.
Dmitrienko, A., Paux, G., Brechenmacher, T. (2014). Power calculations in clinical trials with complex clinical objectives. In press.

Registration Fees:
Biopharmaceutical Section Members: $44
ASA Members: $59
Nonmembers: $74

Each registration is allowed one web connection and one audio connection. Multiple persons are encouraged to view each registered connection (for example, by projecting the webinar in a conference room).

Register



Access Information
Registered persons will be sent an email the afternoon Tuesday, December 2, with the access information to join the webinar and the link to download and print a copy of the presentation slides.